Checkpoint Therapeutics I... (CKPT)
NASDAQ: CKPT
· Real-Time Price · USD
4.26
0.00 (0.00%)
At close: May 29, 2025, 3:59 PM
Checkpoint Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | -41K | n/a | 41K | n/a | 6K | 31K | 31K | 35K | 74K | 48K | 18K | 52K | 16K | 29K | 155K | 68K |
Cost of Revenue | n/a | 12.98M | n/a | 4.48M | 8.5M | 8.3M | 5.5M | 13.95M | 15.83M | 14.24M | 8.87M | 12.05M | 14.67M | 27.66M | 9.38M | 7.2M | 4.21M |
Gross Profit | n/a | 12.94M | n/a | -4.44M | -8.5M | -8.29M | -5.46M | -13.91M | -15.79M | -14.16M | -8.82M | -12.04M | -14.62M | -27.64M | -9.36M | -7.04M | -4.14M |
Operating Income | -11.15M | -28.83M | -9.72M | -6.67M | -10.95M | -10.17M | -7.7M | -16.2M | -18.08M | -16.64M | -10.66M | -14.16M | -16.84M | -29.77M | -11.28M | -9.16M | -6.52M |
Interest Income | 1K | 2K | 2K | 3K | 4K | 3K | 7K | 31K | 43K | 73K | 52K | 22K | 13K | 14K | 13K | 13K | 13K |
Pretax Income | -11.21M | -28.9M | -9.72M | -6.67M | -10.95M | -19.13M | -5.72M | -16.52M | -10.47M | -21.02M | -10.61M | -14.14M | -16.85M | -29.76M | -11.27M | -9.14M | -6.5M |
Net Income | -11.21M | -28.9M | -9.72M | -6.67M | -10.95M | -19.13M | -5.72M | -16.52M | -2.87M | -25.36M | -10.51M | -14.1M | -16.82M | -29.76M | -11.27M | -9.14M | -6.5M |
Selling & General & Admin | 7.36M | 12.02M | 3.36M | 2.23M | 2.45M | 1.88M | 2.24M | 2.28M | 2.29M | 2.48M | 1.85M | 2.13M | 2.24M | 2.13M | 1.92M | 2.11M | 2.37M |
Research & Development | 3.79M | 16.81M | 6.37M | 4.48M | 8.5M | 8.3M | 5.5M | 13.95M | 15.83M | 14.24M | 8.87M | 12.05M | 14.67M | 27.66M | 9.38M | 7.2M | 4.21M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 11.15M | 28.83M | 9.72M | 6.71M | 10.95M | 10.18M | 7.73M | 16.23M | 18.12M | 16.72M | 10.71M | 14.18M | 16.91M | 29.79M | 11.31M | 9.31M | 6.59M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | 100K | 200K | n/a | n/a | n/a | 400K | n/a | 200K | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 28.83M | 9.72M | 6.71M | 10.95M | 10.18M | 7.73M | 16.23M | 18.12M | 16.72M | 10.71M | 14.18M | 16.91M | 29.79M | 11.31M | 9.31M | 6.59M |
Income Tax Expense | n/a | 43.28K | n/a | n/a | -43.28K | n/a | n/a | -31K | -7.61M | 4.34M | -104K | -44K | -26K | -14K | -54K | -55.81K | -55.21K |
Shares Outstanding (Basic) | 598.24K | 39.67M | 43.15M | 36.53M | 32.93M | 27.29M | 19.99M | 15.7M | 11.75M | 10.29M | 8.86M | 8.75M | 8.5M | 7.85M | 7.85M | 7.55M | 7.03M |
Shares Outstanding (Diluted) | 598.24K | 39.67M | 43.15M | 36.53M | 32.93M | 27.29M | 19.99M | 15.7M | 11.75M | 10.29M | 8.86M | 8.75M | 8.5M | 7.85M | 7.85M | 7.55M | 7.03M |
EPS (Basic) | -18.74 | -0.7 | -0.23 | -0.18 | -0.33 | -0.7 | -0.29 | -1.05 | -0.24 | -2.47 | -1.19 | -1.61 | -1.98 | -3.79 | -1.43 | -1.21 | -0.93 |
EPS (Diluted) | -18.74 | -0.7 | -0.23 | -0.18 | -0.33 | -0.7 | -0.29 | -1.05 | -0.24 | -2.47 | -1.19 | -1.61 | -1.98 | -3.79 | -1.43 | -1.21 | -0.93 |
EBITDA | -11.15M | -28.83M | -9.72M | -6.67M | -10.95M | -10.17M | -7.7M | -16.2M | -18.08M | -16.64M | -10.66M | -14.16M | -16.86M | -29.77M | -11.28M | -9.16M | -6.52M |
EBIT | n/a | -28.9M | -9.72M | -6.67M | -10.95M | -10.17M | -7.7M | -16.2M | -18.08M | -16.64M | -10.66M | -14.16M | -16.86M | -29.77M | -11.28M | -9.16M | -6.52M |
Depreciation & Amortization | n/a | -43.28K | n/a | n/a | 43.28K | 43.81K | 7.7M | 357K | -7.57M | 54.88K | 10.66M | 86.06K | 16.86M | 14K | 54K | 55.81K | 55.21K |